We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DAIO:NASDAQData I/O Corporation Analysis

Data as of 2026-06-14 - not real-time

$4.03

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at $4.03, just below the 52‑week high of $4.49, with the 20‑day SMA (3.63) comfortably above both the 50‑day and 200‑day SMAs, suggesting a short‑term bullish bias. However, the RSI sits at 66 — near the overbought zone – and the MACD histogram has turned negative, signaling bearish momentum, while volume has been on a decline and 30‑day volatility exceeds 100%, indicating a choppy market.
Fundamentally, DAIO posted a 47% plunge in revenue and a loss of $0.34 per share, far missing consensus estimates. Gross margins remain respectable at ~48%, but operating margins are deeply negative (‑96%), and the company reports a trailing EPS of –$0.86 with a forward EPS of only $0.06. The balance sheet is relatively clean, with $5.7 M in cash versus $1.2 M of debt, but earnings are weak and ROE is –57%.
Analysts project a target price of $5.00, implying roughly a 24% upside from current levels. The upside is driven primarily by a announced transformational acquisition that could double the company’s size, but the near‑term catalyst is the recent earnings miss and bearish technical signals, creating a mixed outlook.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Quarterly earnings miss and widening loss
  • Bearish MACD crossover and decreasing volume
  • Price approaching resistance with limited upside

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Transformational acquisition expected to boost scale
  • Forward EPS improvement and modest cash cushion
  • Target price suggests ~24% upside despite current volatility

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Potential market expansion in IoT, automotive and edge AI segments
  • Low debt level and adequate cash reserves
  • Long‑term upside tied to successful integration of the acquisition

Key Metrics & Analysis

Financial Health

Revenue Growth-47.40%
Profit Margin-43.20%
P/E Ratio67.2
ROE-57.30%
ROA-23.39%
Debt/Equity11.80
P/B Ratio3.6
Industry P/E36.8

Technical Analysis

TrendNeutral
RSI65.9
Support$2.76
Resistance$4.49
MA 20$3.63
MA 50$3.00
MA 200$3.00
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Target Price$5.00
Upside/Downside24.07%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.84
Volatility100.74%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.